Jan 5, 2026 06:20AM Leerink Partners Assumes Larimar Therapeutics (LRMR) at Outperform

Nov 5, 2025 04:14PM Larimar Therapeutics, Inc. (LRMR) Misses Q3 EPS by 20c

Oct 6, 2025 04:07AM Citizens Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Oct 3, 2025 04:09AM Citizens Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Sep 30, 2025 04:05AM Citizens JMP Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Sep 29, 2025 04:37PM Larimar Therapeutics (LRMR) PT Lowered to $7 at Jones Trading

Sep 29, 2025 02:41PM Leerink on Larimar Therapeutics (LRMR): 'risk/reward profile favorable', PT $25

Sep 29, 2025 07:02AM Larimar reports positive data from Friedreich's ataxia drug study

Sep 16, 2025 06:51AM Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Aug 19, 2025 04:12AM Citizens JMP Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Aug 15, 2025 04:57AM Larimar Therapeutics (LRMR) PT Lowered to $18 at Citizens JMP

Aug 14, 2025 02:19PM Truist Securities Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Aug 14, 2025 02:07PM Guggenheim on Larimar Therapeutics (LRMR): 'remains on track to present initial OLE data in Sept 2025'

Aug 14, 2025 01:59PM Larimar Therapeutics (LRMR) PT Lowered to $12 at Citi

Aug 14, 2025 07:24AM Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 7c

Aug 4, 2025 10:47AM Larimar Therapeutics (LRMR) PT Lowered to $10 at Jones Trading

Jul 29, 2025 04:02PM Larimar Therapeutics announces underwritten public offering

Jul 8, 2025 07:02AM Larimar Therapeutics publishes nonclinical data on nomlabofusp

Jun 25, 2025 06:07AM Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Jun 23, 2025 01:29PM Citi on Larimar Therapeutics (LRMR): 'We are buyers on today’s weakness'

Jun 23, 2025 08:27AM Leerink Partners Reiterates Outperform Rating on Larimar Therapeutics (LRMR)

Jun 23, 2025 07:01AM Larimar Therapeutics (LRMR) Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program

Apr 23, 2025 04:21AM Citizens JMP Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Mar 25, 2025 12:52PM Jones Trading Reiterates Buy Rating on Larimar Therapeutics (LRMR), PT $14

Mar 25, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Mar 25, 2025 04:24AM Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Mar 24, 2025 07:03AM Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c

Mar 24, 2025 07:01AM Larimar Therapeutics (LRMR) Provides Nomlabofusp Development Update

Jan 24, 2025 05:18AM JMP Securities Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)

Dec 17, 2024 06:58AM Larimar Therapeutics (LRMR) PT Lowered to $13 at Baird

Dec 17, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Dec 16, 2024 02:38PM Leerink Partners Reiterates Outperform Rating on Larimar Therapeutics (LRMR)

Dec 16, 2024 02:23PM Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Dec 16, 2024 01:55PM Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Dec 16, 2024 07:02AM Larimar Therapeutics (LRMR) Reports Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

Nov 19, 2024 06:56AM H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)

Nov 18, 2024 07:02AM Larimar Therapeutics (LRMR) Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program

Oct 30, 2024 04:23PM Larimar Therapeutics, Inc. (LRMR) Tops Q3 EPS by 13c

Oct 30, 2024 04:18PM Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR), Opens 90-Day Upside Catalyst Watch

Oct 28, 2024 06:01AM Leerink Partners Reiterates Outperform Rating on Larimar Therapeutics (LRMR)

Oct 3, 2024 06:48AM Wedbush Starts Larimar Therapeutics (LRMR) at Outperform

Sep 11, 2024 04:21PM Jones Trading Starts Larimar Therapeutics (LRMR) at Buy

Sep 4, 2024 06:27AM Baird Starts Larimar Therapeutics (LRMR) at Outperform